Congratulations to our portfolio company Celsius Therapeutics on their successful acquisition by AbbVie. This acquisition will accelerate the development of Celsius’ CEL383, which targets TREM1 to treat Inflammatory Bowel Disease (IBD). We are excited that AbbVie will move this therapy forward in the clinic and make a difference in the lives of patients with IBD. #Biotech #VentureCapital #Healthcare #AmplitudeVC https://lnkd.in/gSQWfwXb
Congratulations!
Congratulations!
We are excited to announce Deciduous Therapeutics as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Deciduous Therapeutics is a San Francisco based, venture backed start-up focused on harnessing the immune system to treat diseases of aging. Specifically, the company is focused on restoring natural killer t-cell function to systemically ablate pathological senescent cells. The company had demonstrated that a single dose of its proprietary NKT agonist is able to selectively remove senescent cells, resulting in disease resolution in both fibrosis and metabolic disease models. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/ggNnNTeh #ARDD2024 #DrugDiscovery #AgingResearch
Leptomeningeal Metastases Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics: Delveinsight Business Research LLP As per DelveInsight, the Leptomeningeal Metastases Market is anticipated to evolve immensely in the coming years owing to the increasing incident population, entry of novel treatment options, development of new diagnostic approaches, and new treatment methods … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
NImmune Biopharma, Inc celebrates AbbVie’s acquisition of Landos Biopharma and its lead clinical candidate NX-13. Terrific validation of TITAN-X, the A.I.-powered precision medicine platform and NImmune team that led the discovery and development of NX-13. NImmune founder and CEO Josep B. founded Landos in 2017 and led its successful growth to a publicly traded >$600M biopharma. TITAN-X, the computational platform that helped characterize the NLRX1 target also discovered NImmune’s best and first-in-class precision medicines, including omilancor, currently in a global Phase 3 program as a once daily oral for Ulcerative Colitis and other inflammatory and autoimmune diseases. Today’s acquisition of Landos and NX-13 by Abbvie reinforces our pioneering work in immunometabolism in I&I and the novel immunoregulatory target discovery programs of the NIMML Institute, as well as the strong efficacy and safety profile of the first-in-class and best-in-class therapeutics we continue to develop at NImmune. PR of today’s news: https://lnkd.in/gCHENN83 Learn more about NImmune here: https://nimmunebio.com/ #Biopharma #Immunology #DrugDevelopment #UlcerativeColitis
Leptomeningeal Metastases Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics: Delveinsight Business Research LLP As per DelveInsight, the Leptomeningeal Metastases Market is anticipated to evolve immensely in the coming years owing to the increasing incident population, entry of novel treatment options, development of new diagnostic approaches, and new treatment methods … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
🚀 Exciting News from VRG Therapeutics! 🚀 We are thrilled to announce that VRG-145, our novel oral combination therapy for migraine prophylaxis, has advanced to the final preclinical stage. This groundbreaking development marks a significant milestone in our efforts to address one of the world's most disabling diseases - migraine, which affects over 1 billion people globally. VRG-145, emerging from our Combi-X project, demonstrates a synergistic effect, enhancing pain relief by 5-10 times compared to its individual drug components. As we prepare for clinical trials expected to begin next year, we are actively seeking strategic partners to join us in revolutionizing migraine treatment. This is a unique opportunity to be at the forefront of delivering an efficacious, well-tolerated, and cost-effective solution to the millions suffering from this debilitating condition. https://lnkd.in/dJtdC_Zm #Biotech #Innovation #Healthcare #MigraineRelief #VRG145 #Preclinical #PartnershipOpportunities #VRGTherapeutics
The Relapsing/Refractory Multiple Myeloma market is witnessing a dynamic evolution, driven by the rise in the number of cases and groundbreaking research and therapeutic innovations. As new treatments emerge and personalized approaches gain traction, the R/R Multiple Myeloma market is set to evolve immensely and lead to a shift towards improved patient outcomes and prolonged survival rates. Currently, some of the leading pharma and biotech giants such as Bristol Myers Squibb, Allogene Therapeutics, Karyopharm Therapeutics Inc., Gracell Biotechnologies, Genentech, Cartesian Therapeutics, Arcellx, Pfizer, Gadeta B.V., a Clade Therapeutics Inc. Company, Celyad Oncology, Ionis Pharmaceuticals, Inc., Ichnos Glenmark Innovation, AbbVie, Caribou Biosciences, ORIC Pharmaceuticals Inc., Juno Therapeutics, Inc., Molecular Templates, Regeneron, Amgen, BeiGene, and others are actively developing novel R/R Multiple Myeloma therapies in the market. Read More: https://lnkd.in/gZ4QVQdF #multiplmyeloma #relapsingmyeloma #refractorymyeloma #cancertreatment #hematology #oncology #medicalresearch #therapeuticinnovation #precisionmedicine #personalizedtherapy #healthcareadvancements #clinicaltrials
Halia Therapeutics, Inc. has announced the completion of enrollment in its Phase I study evaluating its lead asset, HT-6184, for chronic inflammation. HT-6184 is the first drug candidate to target the protein NEK7 through an allosteric mechanism to inhibit NLRP3 inflammasome activity. "Given that NLRP3-induced chronic inflammation is at the root of many diseases, clinical development of an effective medicine that targets an important driver of systemic chronic inflammation could have significant implications in reducing inflammatory signaling and mitigating the risk of chronic diseases in humans." -David Bearss Ph.D. CEO of Halia Therapeutics. #chronicdisease #chronicinflammation #therapeutics #utah #biohive https://lnkd.in/gb2gmefk
Sanofi 𝗵𝗮𝘀 𝗺𝗮𝗱𝗲 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 $𝟴𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝘂𝗽𝗳𝗿𝗼𝗻𝘁 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗯𝘆 Fulcrum Therapeutics, 𝘀𝗲𝗰𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝘅-𝗨.𝗦. 𝗿𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝟯𝟴 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗹𝗼𝘀𝗺𝗮𝗽𝗶𝗺𝗼𝗱. This strategic move places Sanofi in a leading position in the race to market, with plans to seek approval in multiple global markets while Fulcrum retains U.S. rights. The phase 3 trial for losmapimod, targeting facioscapulohumeral muscular dystrophy (FSHD), could potentially pave the way for the first approved therapy for this condition, affecting 𝗮𝗽𝗽𝗿𝗼𝘅𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝟯𝟬,𝟬𝟬𝟬 𝗶𝗻𝗱𝗶𝘃𝗶𝗱𝘂𝗮𝗹𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. alone. With a strong commitment to advancing rare disease treatments, this collaboration underscores Sanofi's dedication to addressing unmet medical needs. https://lnkd.in/gw2i--Y6 #RareDisease #PharmaInnovation #DrugDevelopment #BiotechNews #MedicalBreakthrough
China's NRDL 2023 marked a record for formulary expansion, including several new breakthroughs. Bruce Liu and colleagues discuss the developments in their new article. Learn more about the evolving value rating system as well as the impact on oncology and rare diseases here: https://lnkd.in/eh92SAvF #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher
Vice President Of Business Development at Deep Genomics
1moCongratulations, Team Amplitude Ventures. Onwards and Upwards!